<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RAMELTEON</span><br/><span class="topboxtradename">Rozerem<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">melatonin agonist</span>; <span class="classification">psychotropic agent</span>; <span class="classification">sedative-hypnotic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>8 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Ramelteon is a melatonin receptor agonist with high affinity for melatonin MT<sub>1</sub> and MT<sub>2</sub> receptors and selectivity affinity for the MT<sub>3</sub> receptor in the brain.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The activity of ramelteon at MT<sub>1</sub> and MT<sub>2</sub> receptors is believed to promote sleep, as these receptors, in response to endogenous melatonin, are thought to be involved
         in maintaining the circadian rhythm underlying the normal sleep-wake cycle.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of insomnia characterized by difficulty with sleep onset.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ramelteon; severe hepatic function impairment; (Child-Pugh C class); concurrent use of alcohol, sedative,
         or CNS depressant drugs; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate hepatic function impairment (Child-Pugh B class); pregnancy (category C); depression with suicidal tendencies; concurrent
         use of fluvoxamine; elderly.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Insomnia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 8 mg within 30 min of h.s.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give within 30 min of bedtime.</li>
<li>Do not administer to anyone on concurrent fluvoxamine therapy without alerting physician. This combination causes a dramatic
            increase in ramelteon blood level.
         </li>
<li>Store at 15°30° C (59° 86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Depression, dizziness, fatigue, headache, insomnia, somnolence. <span class="typehead">GI:</span> Diarrhea, unpleasant taste, nausea. <span class="typehead">Musculoskeletal:</span> Arthralgia, myalgia. <span class="typehead">Respiratory:</span> Upper respiratory tract infection. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concurrent use with <b>ethanol</b> produces additive CNS depressant effects; <b>ketoconazole, itraconazole,</b> and <b>fluvoxamine </b>increase ramelteon levels; other CYP1A2 inhibitors (e.g., <b>ciprofloxacin, enoxacin, mexiletine, norfloxacin, tacrine</b>) may also increase ramelteon levels; <b>rifampin</b> decreases ramelteon levels. <span class="typehead">Food:</span> High fat meal, <b>grapefruit</b> or <b>grapefruit juice</b> increase ramelteon level. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 84%. <span class="typehead">Peak:</span> 45 min. <span class="typehead">Distribution:</span> 82% protein bound. <span class="typehead">Metabolism:</span> Rapid and extensive first pass hepatic metabolism; one metabolite, M-II, is active. <span class="typehead">Elimination:</span> Primarily renal. <span class="typehead">Half-Life:</span> 12.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report worsening insomnia and cognitive or behavioral changes.</li>
<li>Monitor for S&amp;S of decreased testosterone levels (e.g., loss of libido) or increased prolactin levels (galactorrhea).</li>
<li> Lab test: Baseline LFTs.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Follow directions for taking the drug (see Administration). </li>
<li>Do not take with or immediately after a high fat meal.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not consume alcohol while taking this drug.</li>
<li>Report any of the following to physician: worsening insomnia, cognitive or behavioral changes, problem with reproductive function.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>